# A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors

> **NCT05120960** · PHASE1 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Brain Tumor

## Interventions

- **DRUG:** tepotinib
- **DRUG:** tepotinib plus osimertinib

## Key facts

- **NCT ID:** NCT05120960
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-02-27
- **Primary completion:** 2024-04-12
- **Final completion:** 2024-04-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** 0 participant accrual
- **Last updated:** 2024-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05120960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05120960, "A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05120960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*